TG Therapeutics stock surged after H.C. Wainwright raised its price target to $70, indicating a potential upside of 76.1%. On the same day, the company reported Q1 2026 revenues of approximately $205 million, driven by BRIUMVI sales. TG Therapeutics also raised its full-year global revenue target to approximately $925 million.
A series of Q1 earnings reports for US mid-cap companies revealed significant misses against analyst expectations across several key sectors. Coinbase Global reported a quarterly loss of $0.17 per share, failing to meet the consensus estimate of $0.36 in earnings. In the renewable energy space, Clearway Energy posted…
Read the full storyCatalyst Pharmaceuticals has reached a definitive agreement to be acquired by Italy-based Angelini Pharma in an all-cash transaction valued at approximately $4.10 billion. Under the terms of the deal, shareholders are set to receive $31.50 per share, representing a 28% premium over the 30-day volume-weighted average…
The financial landscape saw mixed signals as TTEC Holdings reported quarterly earnings of $0.15 per share, missing the Zacks Consensus Estimate of $0.25. Meanwhile, Teleflex Incorporated posted robust revenue of $548.3 million, a 32.3% year-over-year increase, despite reporting a GAAP diluted loss. Adding to the…
Shares of BDX, SHOO, and BRKR climbed following quarterly results that surpassed estimates, with BDX reporting Q2 revenue of $4.7 billion. Although BDX posted an EPS loss of $0.13, the results were impacted by a significant $1.6 billion one-off loss and a $274 million loss from discontinued operations. Meanwhile,…
BioMarin Pharmaceutical has maintained its 'Strong Buy' rating following the strategic acquisition of Amicus Therapeutics and the expansion of its VOXZOGO pipeline. The acquisition has significantly boosted the company's 2026 revenue guidance to a range of $3.825–$3.925 billion, integrating key treatments like…
H.C. Wainwright has significantly raised its price target for TG Therapeutics (TGTX) to $70, implying a potential upside of 76.1%. The revision follows a robust Q1 2026 performance where the company reported revenues of approximately $205 million. This growth was primarily fueled by the success of its flagship…